Preparation of Diphtheria and Pseudomonas Exotoxin A Immunotoxins and Evaluation of Their Cytotoxicity Effect on SK-BR-3, BT-474, and MDA-MB-231 Breast Cancer Cell Lines

Amoozadeh, Sahel; Hemmati, Maryam; Farajollahi, Mohammad M; Akbari, Neda; Tarighi, Parastoo

doi:10.1080/07357907.2019.1655761

Cited by 7 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A lot of PE-based chimeras have been described in the literature, conjugating PE and its derivatives with various antibody formats, such as single-chain antibody (scFv), disulfide-stabilized antibody (dsFv), bispecific antibody, micro-antibody, and trivalent antibody, and have yielded promising results in both clinical and preclinical tests. This conjugation has led to the development of mono-or bivalent immunotoxins, demonstrating significant potential in the field [93][94][95][96][97]. PEA is formed via a receptor-binding (blue), translocation (green), and catalytic domain (red).…”

Section: • Pe Bacterial Expression Systemsmentioning

confidence: 99%

Hosts and Heterologous Expression Strategies of Recombinant Toxins for Therapeutic Purposes

di Leandro,

Colasante,

Pitari

et al. 2023

Toxins

View full text Add to dashboard Cite

The production of therapeutic recombinant toxins requires careful host cell selection. Bacteria, yeast, and mammalian cells are common choices, but no universal solution exists. Achieving the delicate balance in toxin production is crucial due to potential self-intoxication. Recombinant toxins from various sources find applications in antimicrobials, biotechnology, cancer drugs, and vaccines. “Toxin-based therapy” targets diseased cells using three strategies. Targeted cancer therapy, like antibody–toxin conjugates, fusion toxins, or “suicide gene therapy”, can selectively eliminate cancer cells, leaving healthy cells unharmed. Notable toxins from various biological sources may be used as full-length toxins, as plant (saporin) or animal (melittin) toxins, or as isolated domains that are typical of bacterial toxins, including Pseudomonas Exotoxin A (PE) and diphtheria toxin (DT). This paper outlines toxin expression methods and system advantages and disadvantages, emphasizing host cell selection’s critical role.

show abstract

Section: • Pe Bacterial Expression Systemsmentioning

confidence: 99%

Hosts and Heterologous Expression Strategies of Recombinant Toxins for Therapeutic Purposes

di Leandro,

Colasante,

Pitari

et al. 2023

Toxins

View full text Add to dashboard Cite

show abstract

“…In this discipline, a few studies have been carried out on PE. In a trial, PE and DT were conjugated to trastuzumab, a type of monoclonal antibody specific for breast and stomach cancers [154]. This conjugation reduced the viability levels of SK-BR-3 breast cancer cells by 3-fold compared to PE.…”

Section: Exotoxinmentioning

confidence: 99%

Advances on Delivery of Cytotoxic Enzymes as Anticancer Agents

Asrorov

Muhitdinov

et al. 2022

Molecules

View full text Add to dashboard Cite

Cancer is one of the most serious human diseases, causing millions of deaths worldwide annually, and, therefore, it is one of the most investigated research disciplines. Developing efficient anticancer tools includes studying the effects of different natural enzymes of plant and microbial origin on tumor cells. The development of various smart delivery systems based on enzyme drugs has been conducted for more than two decades. Some of these delivery systems have been developed to the point that they have reached clinical stages, and a few have even found application in selected cancer treatments. Various biological, chemical, and physical approaches have been utilized to enhance their efficiencies by improving their delivery and targeting. In this paper, we review advanced delivery systems for enzyme drugs for use in cancer therapy. Their structure-based functions, mechanisms of action, fused forms with other peptides in terms of targeting and penetration, and other main results from in vivo and clinical studies of these advanced delivery systems are highlighted.

show abstract

“…The “B” and “T” domains are responsible for the toxin’s specific binding and cytoplasmic translocation, respectively. Once released into the cytoplasm of host cells, the “A” domain mediates the transference of an adenosine diphosphate ribosyl (ADPR) moiety onto the EF-2 factor ( Figure 2C ) ( 46 ). DT-based immunotoxins have exhibited potent in vitro antitumor activity (IC 50 s =10 -9 –10 -14 ), suggesting it as a suitable agent to be used in targeted cancer therapy ( 45 ).…”

Section: Chimeric Anticancer Toxins With Bacteria-derived Moietiesmentioning

confidence: 99%

Bacteria-derived chimeric toxins as potential anticancer agents

et al. 2022

View full text Add to dashboard Cite

Cancer is one of the major causes of death globally, requiring everlasting efforts to develop novel, specific, effective, and safe treatment strategies. Despite advances in recent years, chemotherapy, as the primary treatment for cancer, still faces limitations such as the lack of specificity, drug resistance, and treatment failure. Bacterial toxins have great potential to be used as anticancer agents and can boost the effectiveness of cancer chemotherapeutics. Bacterial toxins exert anticancer effects by affecting the cell cycle and apoptotic pathways and regulating tumorigenesis. Chimeric toxins, which are recombinant derivatives of bacterial toxins, have been developed to address the low specificity of their conventional peers. Through their targeting moieties, chimeric toxins can specifically and effectively detect and kill cancer cells. This review takes a comprehensive look at the anticancer properties of bacteria-derived toxins and discusses their potential applications as therapeutic options for integrative cancer treatment.

show abstract

Preparation of Diphtheria and Pseudomonas Exotoxin A Immunotoxins and Evaluation of Their Cytotoxicity Effect on SK-BR-3, BT-474, and MDA-MB-231 Breast Cancer Cell Lines

Cited by 7 publications

References 41 publications

Hosts and Heterologous Expression Strategies of Recombinant Toxins for Therapeutic Purposes

Hosts and Heterologous Expression Strategies of Recombinant Toxins for Therapeutic Purposes

Advances on Delivery of Cytotoxic Enzymes as Anticancer Agents

Bacteria-derived chimeric toxins as potential anticancer agents

Contact Info

Product

Resources

About